Transforming the early detection
and intervention of cancer
Our Unique Biomarker
OncAlert Labs develops tests based on patented technology that detects specific protein markers known to indicate an elevated risk for early stage cancers, even prior to observation of visual or physical symptoms.
Actionable Insights for Earlier Oral Cancer
OraMark’s oral rinse collection method is easy to administer and non-invasive for the patient. The test delivers accurate, quantitative results that help optimize patient management and surveillance both pre- and post-biopsy.
Featured News and Events
Nov 14, 2016 |
Vigilant Biosciences Announces New Distribution Partnership Agreements for OncAlert® Oral Cancer Product Line for Spain, Portugal and Germany
Vigilant Biosciences today announced exclusive multi-year distribution agreement for sales and marketing of its OncAlert® Oral Cancer product line in Spain, Portugal and Germany. The Company made the announcement in conjunction with the MEDICA Trade Fair, where the Company is showcasing its OncAlert Oral Cancer product line in Hall 16, booth #D04.      
Oct 31, 2016 | Crain's Miami
If I Knew Then: Matthew H. J. Kim
The Mistake: I fell in love with a technology before understanding the impact or value the technology can have in the real world. In my prior medical startup, I created a drug delivery platform which had a very novel way of delivering medication to the lungs systemically. I licensed and started the company and raised […]
Oct 18, 2016 | Dentistry Today
Save Lives With Simple Oral Cancer Screenings
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity, and pharynx) cancer each year worldwide, with mortality rates reaching up to 292,000 deaths each year.1 In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting […]